Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Johnson & Johnson SWOT & PESTLE Analysis

ID : 52257953| Dec 2017| 12 pages

COMPANY PROFILE -Johnson & Johnson

Business Sector :Consumer Products, Medical equipment and Pharmaceuticals

Operating Geography :United States, North America, Global

About Johnson & Johnson :

Johnson & Johnson is an American consumer products, medical equipment and pharmaceutical manufacturing company founded in 1886. It's headquartered in New Brunswick, New Jersey. It has 230 subsidiary companies and its products are sold in over 170 countries. It has around 125,000 employees with offices in more than 60 countries as of 2016. Their products marketed internationally include those produced in the U.S. and by subsidiaries abroad.

Johnson & Johnson Revenue :

$71.9 Billion (2016)

Competitive Analysis of Johnson & Johnson

SWOT
PESTLE
The SWOT analysis for Johnson & Johnson is presented below:
Strengths
Weaknesses
1. Revenue spread across many product categories
2. Enjoys a healthy brand equity in the minds of shareholders
3. R&D Focus and Integrated Supply Chain
1. Uncertainty of the research outcomes and regulatory approvals
2. Negative word of mouth as a result on ongoing litigations
Opportunities
Threats
1. Opportunity to cross sell products
2. Growth in revenue streams through recent acquisitions
3. Robust growth opportunities in the pharmaceutical segment
1. Interruptions in sourcing manufacturing materials
2. Changes in tax liabilities or sudden regulatory scrutiny
3. Healthcare reforms and pricing pressures can negatively impact the Company’s Pharmaceutical and Medical Devices segments
SWOT & PESTLE (combined)
Complete Report
USD 11.53
*
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Johnson & Johnson

Strength

1. Revenue spread across many product categories: Johnson & Johnson revenue sources are broadly spread across pharmaceuticals, consumer products and medical devices. All three business sectors are well positioned to address the changing needs of the customers and patients. The sales in the Consumer segment were $13.3 billion, in the Pharmaceutical segment were $33.5 billion whereas in the Medical Devices segment were $25.1 billion in 2016. Excluding the effect of acquisitions, divestitures, on the operational front, global sales jumped 7.6%, domestic sales escalated 9.5% and international sales shot up by 5.6%.

2. Enjoys a healthy brand equity in the minds of shareholders: The Company has $72 billion in revenue and coupled with its solid balance sheet across the last 4 quarters makes the New Jersey-based health care giant the first choice of many mutual fund portfolios. Johnson & Johnson shares have been on a roll for five years, doubling in price from about $67 in August 2012 to $133 and change in 2017. The shares are up 16 percent so far in 2017.

3. R&D Focus and Integrated Supply Chain: Research activities represent a significant part of the Company’s businesses. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products. In terms of worldwide costs of research and development activities, 9.1 billion dollars were spent in 2016, 9 billion dollars were spent in 2015 and 8.5 billion dollars were spent in 2014. Research facilities are located in the United States, Canada, India, China, Netherlands, France, Switzerland, Germany, Israel, Belgium, Japan, Singapore, Brazil and Britain. They aim to utilize operational efficiency and a robust supply chain to ensure operating margins are at benchmark levels.

Weakness

This section is available only in the Complete report on purchase.

Opportunity

1. Opportunity to cross sell products: Johnson & Johnson has a wide spectrum of products available across pharmaceuticals, medical devices and consumer products. As a result, it can diversify its cross sell offerings on retail shelves. A consumer is more likely to buy multiple Johnson & Johnson products in a single transaction because of this opportunity of being cross marketed at a retail level.

2. Growth in revenue streams through recent acquisitions: In the last year alone, Johnson & Johnson completed 14 acquisitions and major licensing deals including 8 divestitures, positioning themselves for sustainable growth and profit for the next few years. Their acquisition of Abbott Medical Optics, which happened in the beginning of 2017, shows their flexibility to invest in diverse areas of specializations across the spectrum of health care. All in all, the corporation consists of 230 subsidiary companies with businesses spread across 60 countries. Good management in these newly acquired businesses can boost their bottom line. As a result, the opportunity to expand the business and thrive looks bright for the near future.

3. Robust growth opportunities in the pharmaceutical segment: There is ample space for increasing penetration in markets such as anti-coagulants, psoriasis, and long-acting anti-psychotics. DARZALEX®, IMBRUVICA®, and STELARA® drugs which help in Crohn’s disease were submitted to FDA and EMA (European Medicines Agency) for approval in early 2016, which have been approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma and J&J hopes to launch them shortly and capitalize on its success. They are also expecting regulatory approval for Guselkumab and Sirukumab in the near future.

Threat

This section is available only in the Complete report on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 11.53
*
Great quality, Affordable pricing.
Safe and secure payments

Check out analysis of other relevant companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
Copyrights and Disclaimer

Johnson and Johnson SWOT and PESTLE analysis has been conducted by Sohum Mishra and reviewed by senior analysts from Barakaat Consulting.

Copyright of Johnson and Johnson SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions for usage guidelines.

The text on www.swotandpestle.com are the property of Barakaat Consulting. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible for omissions or errors in our pages or any links on any of our pages. Analyses published by us above may not totally reflect the company's opinions, reader's discretion is advised. Users have the right to choose the products that suits them the most.

Johnson & Johnson SWOT & PESTLE Analysis
Price : USD 11.53